Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Long-Term Investments (2021 - 2025)

Ovid Therapeutics' Long-Term Investments history spans 5 years, with the latest figure at $42.0 million for Q4 2025.

  • For Q4 2025, Long-Term Investments rose 100.06% year-over-year to $42.0 million; the TTM value through Dec 2025 reached $42.0 million, up 100.06%, while the annual FY2025 figure was $42.0 million, 100.06% up from the prior year.
  • Long-Term Investments reached $42.0 million in Q4 2025 per OVID's latest filing, up from $20.9 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $42.0 million in Q4 2025 to a low of $1.6 million in Q2 2021.
  • Average Long-Term Investments over 5 years is $14.1 million, with a median of $16.5 million recorded in 2023.
  • Peak YoY movement for Long-Term Investments: surged 639.07% in 2023, then fell 5.06% in 2025.
  • A 5-year view of Long-Term Investments shows it stood at $1.6 million in 2021, then surged by 244.52% to $5.6 million in 2022, then soared by 213.49% to $17.6 million in 2023, then increased by 18.99% to $21.0 million in 2024, then soared by 100.06% to $42.0 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Long-Term Investments are $42.0 million (Q4 2025), $20.9 million (Q3 2025), and $20.9 million (Q2 2025).